Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea

Background: Thyroid cancer has become the most common cancer in Korea. Generally, thyroid cancer patients have a good prognosis; however, 15–20% of patients experience recurrence or distant metastasis or are refractory to standard treatment. We assessed the safety of sorafenib and lenvatinib in pati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Front Endocrinol (Lausanne)
Hauptverfasser: Kim, Soo Young, Kim, Seok-Mo, Chang, Hojin, Kim, Bup-Woo, Lee, Yong Sang, Chang, Hang-Seok, Park, Cheong Soo
Format: Artigo
Sprache:Inglês
Veröffentlicht: Frontiers Media S.A. 2019
Schlagworte:
Endocrinology
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6581694/
https://ncbi.nlm.nih.gov/pubmed/31244783
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2019.00384
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge